IntelGenx Corp.
OTC Bulletin Board : IGXT

IntelGenx Corp.

September 10, 2007 08:30 ET

IntelGenx Proprietary Delivery Technology Tested in Cannasat Therapeutics' Phase I Study for Drug Treatment for Neuropathic Pain

SAINT LAURENT, QUEBEC--(Marketwire - Sept. 10, 2007) - IntelGenx Technologies Corp. (OTCBB:IGXT.OB) ("IntelGenx"), a drug delivery company, announced today that its proprietary SL tablet technology will be included in the Phase 1 Study of CAT 310, a potential new treatment for neuropathic pain being developed by Cannasat Therapeutics Inc., a Canada-based early stage pharmaceutical R&D company.

IntelGenx's SL tablet delivery system is intended to (i) significantly improve the bioavailability of the active ingredients in Cannasat's lead product, CAT 310, and (ii) create a rapid onset of action.

Horst G. Zerbe, President and CEO of IntelGenx, said, "The study is very important for both companies since it will be the first time that the new formulation is tested in humans and is intended to provide proof of concept for IntelGenx's muco-adhesive drug delivery technology."

Cannasat Therapeutics announced on August 23, 2007 that Health Canada has approved a Phase 1 clinical study for Cannasat's lead product CAT 310. The product is Cannasat's first cannabinoid based product designed to manage neuropathic pain and other disorders. Enrolment in Canada for this trial is expected to begin in early October 2007.

David Hill, CEO of Cannasat, stated in that release, "This significant milestone will transform the company (Cannasat) from a pre-clinical research company to a Phase 1 pharmaceutical company engaged in developing safe and effective cannabinoid products that target unmet medical needs."

IntelGenx and Cannasat established their business relationship in 2006 with the intent to develop a tablet formulation for the rapid and complete absorption of Tetrahydrocannabinol. Based on that successful collaboration, the companies have expanded their relationship and included another development project. In addition, Horst Zerbe has been named a member of Cannasat's Scientific Advisory Board.

Under both agreements, Intelgenx provides pharmaceutical development services to Cannasat. It receives service fees for its development services and is entitled to a royalty on product sales once the product enters the market.

About IntelGenx Technologies

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. Since January 2007, IntelGenx has been trading on the OTCBB.

To learn more about IntelGenx, please visit the Company's website at http://www.intelgenx.com. To quickly access the Company's Investor Fact Sheet, please visit www.cfsg1.com.

About Cannasat Therapeutics

Founded in 2004, Cannasat is an early stage pharmaceutical research and development company. Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications which are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat (TSX VENTURE:CTH) is available at http://www.cannasat.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Pursuant to a June 1, 2007 contract, Consulting For Strategic Growth1, Ltd. ("CFSG1") provides IntelGenx Corp. ("the Company") with consulting, business advisory, investor relations, public relations and corporate development services. Independent of CFSG1's receipt of cash compensation from the Company, CFSG1 may choose to purchase the Company's common stock and thereafter liquidate those securities at any time it deems appropriate to do so.

Contact Information